Abstract
Proto oncogenes represent a family of genes which when activated have been shown to play a role in the pathogenesis of a number of malignancies in vertebrate species including humans.1,2 In physiologic states these same genes are known to play a role in the normal cell growth control and differentiation. The HER2/neu gene is a member of the Type I receptor tyrosine kinase (RTK) group which is one of the subfamilies in the proto oncogene family and encodes a 185kD surface membrane receptor protein. This gene has been localized to chromosome 17q21,1 and the encoded protein is expressed in a wide variety of tissues including the skin, oral mucera, breast, ovary, endometrium, lung, liver, pancreas, small and large bowel, kidney, bladder and the central nervous system as well as some connective tissues.4–5 The exact physiological role of the HER2/neu protein in these tissues is not completely understood, but like other proto oncogenes it is believed to play an important signaling role in cellular proliferation and differentiation processes. Current data suggests that it forms hetero-dimers with other members of the RTKI family (such as HER 1, HER3 and HER4 in response to various ligands known as heregulins.6–8 Activation of HER2/neu results in an increase its kinase activity which in turn initiates signal transduction resulting in either cellular proliferation and/or differentiation, depending on the ligand as well as the conditions.9–14 In human breast cancers, a non-inherited alteration occurs in this gene in 25–30% of cases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Slamon, D.J. Proto-oncogenes and human cancers. N Engl J Med 317: 955–957, 1987.
Slamon, D.J. Oncogenes and human malignancy, pp 226–229. In: Cline, M.J. Moderator. Oncogenes: Implications for the diagnosis and treatment of cancer. Ann Int Med 101:223–233, 1984.
Shih C, Padhy L, Murray M, et al.,Transforming genes of carcinomas and neuroblastomas introduced into muonse fibroblasts. Nature 1981; 260: 261264.
Coussens L, Yang-Feng TL, Liao YC, et al.,Tyrosine kinase receptor with extensive homology fo EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132–1139.
King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb-B-2related gene in human mammary carcinoma. Science 1985; 229: 974–6.
Carraway K, Cantley L. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994; 78: 5–8.
Sliwkowski M, Schaefer G, Akita R, et al., Coexpression of erB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269: 15661–14665.
Plowman G, Culouscou J-M, Whitney G, et al., Ligand-specific activiation of HER4/p180erB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993; 90: 1746–1750.
Reese DM and Slamon DJ. HER-2/neu Signal Transduction in Human Breast and Ovarian Cancer. Stem Cells 1997; 15: 1–8.
Wen D, Suggs SV, Karunagaran D, et al. Structural and functional aspects of the multiplicity of neu differentiation factors. Molecular and Cellualr Biology 14: 1909–1919, 1994.
Wen D, Peles E, Cupples R, et al. Neu differentiation factor: a transmembrane glycoprotein containing and EGF domain and an immunoglobulin homology unit. Cell 69: 559–572, 1992.
Falls, DL, Rosen KM, Corfas G, et al. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 72: 801, 1993.
Marchionni M, Goodearl A, Chen M, et al. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362: 312, 1993.
Peles E, Ben-Levy R, Tzahor E, et al. Cell-type specific interaction of neu differentiation factor (NDF/heregulin) with neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12: 961–971, 1993.
Slamon DJ, Clark GM, Wong SG, et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182.
Slamon DJ, Godolphin W, Jones LA, et al., Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712.
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11: 1936–1942, 1993.
Press MF, Hung G, Godolphin W, et al., Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771–2777.
Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10: 1044–1048, 1992.
Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D, for the Toronto Breast Cancer Study Group: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16: 1340–1349, 1998.
Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 42854289, 1992.
Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63–72, 1996.
Roche and Ingle, Increased HER2 with U.S. FDA-Approved Antibody J Clin Oncol 17: 434–435, 1999(letter).
Diane Maia, Immunohistochemical Assays for HER2 Overexpression J Clin Oncol 17: 434, 1999.
Pegram M, Lipton A, Hayes D, et al: Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER-2/neu Monoclonal Antibody Plus Cisplatin in Patients With HER-2/neu-Overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. J Clin Oncol 16: 2659–2671, 1998.
Pegram MD, Pauletti G, and Slamon DJ., HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res and Treat 1998, 52 (1–3): 65–77.
Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-pl85HER2 monoclonal antibodies. Cancer Immunol Immunother 37: 255–263, 1993.
Herceptin (Trastuzumab) anti-HER2 monoclonal antibody: product package insert, Genentech, Inc. South San Francisco, CA, copyright September, 1998.
Pegram MD, Baly D, Wirth C, et al., Antibody dependent cell-mediated cytotoxicity in breast cancer patients in Phase III clinical trials of a humanized anti-HER2 antibody. Proc Am Assoc Cancer Res 1997;3 8:602(abstract).
Pietras RJ, Pegram MD, Finn RS, et al: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235–2249, 1998.
Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829–1838, 1994.
Aboud-Pirak E, Hurwitz E, Pirak ME, et al: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80: 1605–1611, 1988.
Pegram M, Hsu S, Lewis G, et al., Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241–2251, 1999.
Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744, 1996.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G, Slamon D: Efficacy and Safety of Herceptin (Humanized Anti-HER2 Antibody) as a Single Agent in 222 Women with HER2 Overexpression who Relapsed Following Chemotherapy for Metastatic Breast Cancer. Proc Am Soc Clin Oncol 17: 376, 1998.
Vogel CL, Cobleigh MA, Tripathy D, et al., Efficacy and safety of Herceptin (Trastuzumab, humanized anti-HER2 antibody) as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC). Breast Cancer Res and Treat 1998; 50: 232a.
Pegram M, Lipton A, Hayes D, et al: Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER-2/neu Monoclonal Antibody Plus Cisplatin in Patients With HER-2/neuOverexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. J Clin Oncol 16: 2659–2671, 1998.
Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Addition of Herceptin (Humanized anti-HER-2 Antibody) to First Line Chemotherapy for HER2 Overexpressing Metastatic Breast Cancer (HER2+MBC) Markedly Increases Anticancer Activity: A Randomized, Multinational Controlled Phase III Trial. Proc Am Soc Clin Oncol 17: 377, 1998.
Norton L, Slamon D, Leyland-JHones B, et al., Overall Survival (OS) Advantage to Simultaneous chemotherapy (Crx) Plus the Humanized AntiHER2 Monoclonal Antibody Herceptin (H) in HER2-Overexpressing (HER2+) Metastatic Breast Cancer (MBC). Prc Am Soc Clin Oncol 1999; 18: 483 (abstract).
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson C: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Medicine 330: 1260–1266, 1994.
Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET: erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer. J Natl Cancer Inst 90: 1346–1360, 1998.
Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor-Negative Breast Cancer. J Natl Cancer Inst 90: 1361–1370, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Pegram, M.D., Konecny, G., Slamon, D.J. (2000). The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer. In: Gradishar, W.J., Wood, W.C. (eds) Advances in Breast Cancer Management. Cancer Treatment and Research, vol 103. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3147-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3147-7_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-3149-1
Online ISBN: 978-1-4757-3147-7
eBook Packages: Springer Book Archive